|Bid||4.0300 x 39400|
|Ask||4.0500 x 45100|
|Day's Range||3.8300 - 4.0600|
|52 Week Range||3.0000 - 14.2700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||9.60|
|Earnings Date||Oct 05, 2022 - Oct 10, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.20|
Subscribe to Yahoo Finance Plus to view Fair Value for TLRY
On July 15, a high-profile meeting about cannabis law in the E.U. between delegations from Germany, Malta, Luxembourg, and the Netherlands yielded an enigmatic yet telling tidbit about the future of legalization. When paired with Germany's moves in June to start the process of legalizing marijuana by evaluating the relevant consumer protection standards and holding hearings, it's clear that a green wave of legalization in the E.U. could be building, and rapidly.
Zacks.com users have recently been watching Tilray Brands, Inc. (TLRY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tilray Brands (NASDAQ: TLRY) CEO Irwin Simon is no stranger to making lofty projections. Simon's goal to hit $4 billion in annual revenue assumes that legalization takes place in Europe and the U.S. And in a recent interview with CNBC, he said that once that happens, there won't be another company out there "that will have the assets and the ability to grow and build brands like we will." Tilray also has convertible notes in multi-state marijuana operator MedMen Enterprises that it could seek to convert and take a stake in once legalization takes place (currently it would run into issues owning a stake in the business given the federal ban on pot in the U.S.).